# MacroGenics

Source: https://onco.cc/companies/macrogenics/  
OnCo record `macrogenics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MacroGenics is the antibody engineering company behind margetuximab and several bispecific and ADC programmes.

## Summary

MacroGenics, based in Rockville, Maryland, and listed as MGNX, is an antibody engineering company behind margetuximab and a series of bispecific and antibody-drug conjugate programmes. Its Fc-optimisation and DART bispecific platforms produced margetuximab, sold as Margenza and approved in 2020 for HER2-positive breast cancer, vobramitamab duocarmazine, a B7-H3 ADC paused after toxicity, and lorigerlimab, a PD-1 by CTLA-4 bispecific. OnCo links it to HER2-positive breast cancer and to the margetuximab drug record. Whether platform companies can turn engineering advantages into products that beat entrenched antibodies is the question its record poses. Margetuximab has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-07
- HQ: Rockville, MD
- Type: biotech
- Website: https://www.macrogenics.com
- Ticker: MGNX

## Sources

- Official website: https://www.macrogenics.com

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Lorigerlimab](https://onco.cc/drugs/lorigerlimab/), [Margetuximab](https://onco.cc/drugs/margetuximab/)
- trials: [A Study of Lorigerlimab in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct06730347/), [Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer](https://onco.cc/trials/nct04082364/), [Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer](https://onco.cc/trials/nct02492711/), [Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Di](https://onco.cc/trials/nct07071961/)

---
JSON: https://onco.cc/api/v1/entities/macrogenics.json